Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus definitive concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
CTR20202712Phase 3Active
- Sponsor
- MedImmune
- Start
- Jun 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by MedImmune. Started Jun 2021; status: active.
02
Drugs
durvalumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20202712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202712.